Bartek Ingredients Inc. Overview
Bartek Ingredients is a narrowly focused acidulant specialist. It describes itself as the world's largest producer of malic acid and food-grade fumaric acid, and as the only North American producer vertically integrated from maleic anhydride through to finished food acids. From two plants in Southern Ontario it supplies hundreds of food, beverage, confectionery, bakery, animal nutrition and industrial customers in more than 40 countries, largely through distributors. Revenue is about USD 65 million. The company is small but strategically placed: it is the Western-hemisphere alternative to Asian malic and fumaric supply. It is completing a new plant, budgeted at CAD 192.5 million, intended to double capacity. In 2026 it became a consolidated, roughly 50%-owned subsidiary of ICL Group, which intends to acquire the remainder and fold Bartek into a new Nutrition Solutions division from January 2027.
PitchBook separately lists 109 employees (undated). The gap between the 160 jobs cited by the Government of Canada in November 2024 and the aggregator estimates of 106–109 is unresolved. The government figure is the more authoritative, since it is tied to a funding agreement.
What the company does. Bartek manufactures three chemically linked products. Maleic anhydride is the intermediate. Malic acid and fumaric acid are made from it and sold as food-grade acidulants. Around these it has built a small portfolio of branded specialty derivatives: buffered salts, liquid solutions and bakery preservation systems.
Company's own description. Bartek publishes no annual report. Its press-release boilerplate describes it as established in 1969, headquartered in Stoney Creek, operating two production facilities in Southern Ontario registered to ISO 9001:2015, holding BRC Global Standard for Food Safety certification, and distributing to more than 40 countries (releases of 2019–2022). ICL's December 2025 announcement describes Bartek as the global leader in food-grade malic and fumaric acid, serving hundreds of customers and distributors in food, beverage, confectionery, bakery and other end-markets.
Independent characterization. Bartek is a single-chemistry, single-region manufacturer with global sales. Its economics are those of a mid-scale process-chemicals business. Capacity utilisation, feedstock cost and import competition from Asia drive margins. The specialty brands are a deliberate attempt to move part of the mix from price-driven commodity acid to formulated, application-specific ingredients.
Revenue model. Revenue is 100% product sales. No service, subscription or licensing revenue is disclosed. The split between commodity acids and branded specialties is not publicly disclosed.
Value chain position. Bartek sits mid-stream. It sells to food and beverage manufacturers and industrial users, directly and through a global distributor network.
Customer types and end-markets.
Strategy
No annual report or investor day exists for Bartek. Strategy is reconstructed from statements by management, the Government of Canada and ICL.
Stated themes.
-
Invest ahead of demand. The 2020 expansion release framed capacity investment as staying ahead of growth in food-grade malic and fumaric acid. The new plant extends that logic by doubling capacity.
-
Leadership through integration. Management consistently stresses being the largest producer and the only vertically integrated North American one.
-
Move up the value curve. Since 2021 Bartek has launched branded specialty ingredients aimed at specific formulation problems, starting with Pecmate.
-
Sustainability as a plant design goal. The new facility is projected by the company to cut greenhouse gas emissions per unit by more than 80%.
-
Scale through ICL. CEO Andrew Ross has said Bartek expects to capture a larger share of the functional food ingredients market using ICL's global scale, technical expertise and R&D.
Initiatives in the last 24 months.
Financial targets. Bartek has issued no guidance. ICL's 2026 guidance is consolidated adjusted EBITDA of USD 1.5–1.7 billion, with no Bartek-specific target.
Products & Services
Pricing is not publicly disclosed for any product.
Technical service and application support are provided alongside product sales. They are not separately monetised as far as public sources show.
Product Portfolio
| Product | Description | Key capability | Target customer | Launch | Source |
|---|---|---|---|---|---|
Malic acid (food grade) | Core acidulant; apple-like and citrus-like sourness | Intensifies flavour, improves aftertaste, broadens flavour profile | Beverage, confectionery, food manufacturers | Legacy | TorQuest release 2018 |
Fumaric acid (food grade) | Strong, low-hygroscopicity acidulant | Extends shelf life, improves machinability, lowers cost-in-use | Bakery, juices, candies, jams and jellies | Legacy | TorQuest release 2018 |
Fumaric acid (feed and industrial) | Acidifier and chemical intermediate | Positioned to displace antibiotics in feed | Animal nutrition, industrial users | Legacy | Bartek release 2019 |
Maleic anhydride | Intermediate chemical supporting malic and fumaric production | Vertical integration; merchant sales | Internal use; industrial customers | Legacy | TorQuest release 2018 |
EasyAcid Malic Solution | Liquid malic acid at customised solids, typically 50% | Removes the dissolving step, cuts blending errors and dust | RTD sports and energy drinks, sparkling water, sauces, dressings | Shown 2022 | Bartek release; Nutritional Outlook |
Pecmate Pectin Enhancer | Sodium hydrogen malate buffered salt | Prevents pH creep and pre-gelling in pectin gummies; raises throughput, cuts scrap | Gummy supplement and confectionery makers, contract manufacturers | 2,021 | Nutraceuticals World; Nutritional Outlook |
Pecmate K | Potassium-based equivalent of Pecmate | Removes sodium from the ingredient legend; higher solubility | Same as Pecmate | 2,022 | Trade press 2022 |
Uplift Taste Modification Technology | Buffering alternative to citric acid and sodium citrate | Rounds flavour; masks off-notes from actives | Beverage and gummy formulators | 2,023 | Food Ingredients First |
Uphold Clean Natural Mold Inhibitor Booster | Boosts natural mould inhibitors in bread | Clean-label shelf-life extension | Industrial bakeries | By 2024 | Nutraceuticals World |
Uphold Bread Preservation Technology | Bread preservation system | Shelf-life extension | Industrial bakeries | — | LeadIQ company description |
Upscale Artisan Bread Technology | Artisan-style bread technology | Details not publicly verified | Bakeries | — | LeadIQ company description |
Refortify | Electrolyte products | Details not publicly verified | Health and wellness brands | — | LeadIQ |
Financial Narrative
Bartek publishes no financial statements. The only verified figure is annual revenue of about USD 65 million (ICL, December 2025). Every other cell is blank, meaning not publicly disclosed.
Income statement (Bartek)
Revenue CAGR cannot be calculated from one data point.
Balance sheet (Bartek)
Cash flow (Bartek)
Ratios (Bartek)
Transaction-derived data points
Commentary. Three points can be made. First, the plant budget of CAD 192.5 million is several times annual revenue once converted to US dollars. The balance sheet is therefore dominated by a single construction asset and whatever debt funds it. Bartek's debt is not disclosed. Second, ICL's investment is described as a cash investment for about 50% of the company. Whether the cash went into Bartek (primary capital, which would help fund the plant) or to TorQuest (secondary sale) is not publicly disclosed. This matters for interpreting the implied valuation. If the money was primary, the USD 180 million figure is a post-money value. Third, the 2.8x equity-to-revenue multiple excludes debt. Enterprise value multiples cannot be computed.
Parent context: ICL Group consolidated (ICL Q2 2026 Form 6-K)
Bartek's revenue is under 1% of ICL's FY2025 sales.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Families
| Product family | Contents |
|---|---|
Malic acid | Granular and powder food-grade malic acid; EasyAcid liquid |
Fumaric acid | Food-grade and industrial fumaric acid |
Maleic anhydride | Intermediate, largely captive; some merchant sales |
Specialty solutions | Pecmate, Pecmate K, Uplift, Uphold, Upscale, Refortify |
Revenue by Segment
| Metric | FY2025 |
|---|---|
Total revenue, approximate (USD Mn) | 65 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Half-Yearly)
| Metric | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|
Industrial Products sales (USD Mn) | 1,254 | 663 | 763 |
Potash sales (USD Mn) | 1,714 | 788 | 971 |
Phosphate Solutions sales (USD Mn) | 2,333 | 1,210 | 1,401 |
Growing Solutions sales (USD Mn) | 2,063 | 1,035 | 1,156 |
Industrial Products operating income (USD Mn) | 220 | 116 | 186 |
Potash operating income (USD Mn) | 298 | 108 | 190 |
Phosphate Solutions operating income (USD Mn) | 342 | 181 | 161 |
Growing Solutions operating income (USD Mn) | 135 | 63 | 62 |
Income Statement
| Metric | FY2025 |
|---|---|
Revenue, approximate (USD Mn) | 65 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Phase-one consideration (USD Mn) | 90 | ICL release Dec 2025 |
Stake acquired (%) | 50 | ICL release Dec 2025 (approximate) |
Implied 100% equity value (USD Mn) | 180 | Analyst calculation |
Implied equity value / revenue (x) | 2.8 | Analyst calculation: 180 / 65 |
ICL liability for non-controlling-interest put options (USD Mn) | 49 | ICL Q2 2026 Form 6-K |
New plant project budget (CAD Mn) | 192.5 | Government of Canada, Nov 2024 |
Federal SIF contribution (CAD Mn) | 27 | Government of Canada, Nov 2024 |
Income Statement and Per-Share Data
| Metric | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|
Sales (USD Mn) | 7,153 | 3,599 | 4,158 |
Gross profit (USD Mn) | 2,186 | 1,114 | 1,290 |
Operating income (USD Mn) | 580 | 366 | 501 |
Adjusted EBITDA (USD Mn) | 1,488 | 710 | 860 |
Net income attributable to shareholders (USD Mn) | 226 | 184 | 263 |
Diluted EPS (USD) | 0.18 | 0.14 | 0.20 |
Operating cash flow (USD Mn) | 1,056 | 434 | 485 |
Capex (USD Mn) | 824 | 392 | 332 |
R&D expenses (USD Mn) | 70 | 37 | 29 |
Geographic Revenue
| Metric | FY2018 | FY2019 | FY2020 | FY2022 | FY2025 |
|---|---|---|---|---|---|
Countries served (minimum) | 35 | 35 | 40 | 40 | 40 |
Capital Markets
| Metric | Bartek | Comment |
|---|---|---|
Implied equity value / sales (x) | 2.8 | Analyst calculation from the ICL phase-one price |
Analyst Conclusions
Guidance and consensus. Bartek has given none. The only forward statements are that the new plant should complete in 2026, that it will significantly expand capacity, and that phase two of the ICL acquisition will follow business and integration milestones.
Bull case.
-
Capacity plus distribution. Doubling capacity at the moment a global food ingredients sales force becomes available is the right sequence. ICL already sells into the same food customers.
-
Structural supply-security premium. Bartek is the only integrated North American producer. Large food companies that want non-Asian supply have few alternatives.
-
Mix upgrade. The specialty line gives a route to higher margins than commodity acid, and ICL's R&D can accelerate it.
Bear case.
-
Execution record on the plant. A three-year delay and a rising budget suggest that commissioning risk is real, and volumes may arrive later than planned.
-
Volume into a price-sensitive market. ICL's own commentary says food customers are resisting price increases. Doubling capacity may require price concessions.
-
Structural cost and feedstock position. Asian producers remain the low-cost reference, and the petrochemical route is out of step with bio-based demand until the fermentation research delivers.
Catalysts and monitorables for the next 12 months.
It is a small, private, technically focused chemical producer that has just changed hands for the second time in eight years.
What the public record does support is a clear strategic picture. Bartek holds a defensible position in two niche acidulants, with a geographic and integration advantage in North America that competitors cannot easily copy. Its owners have spent heavily to protect that position, first through incremental expansions and then through a plant costing about three times annual revenue. That project is late and over its original budget, and it is the single point on which the next three years depend.
ICL's entry improves the odds. It brings distribution, technical resources and a balance sheet rated investment grade. The staged structure also shows caution: ICL bought half, tied the rest to milestones, and booked a USD 49 million liability for the remainder. That is how a buyer behaves when it likes the asset and wants proof on execution.
On balance the position is constructive but unproven. The assets and market position are credible. The valuation of roughly 2.8 times revenue on an equity basis is reasonable only if the new plant delivers.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Source |
|---|---|---|---|---|
Andrew Ross | Chief Executive Officer | In role by Nov 2024; start date not confirmed | Chairman, GreenMantra Technologies; roles at GCP Applied Technologies and Vibrantz Technologies | Government of Canada; ZoomInfo |
| — | Chief Financial Officer | — | — | LeadIQ |
| — | Chief Operating Officer | — | — | LeadIQ |
Mohammad Emami | Director of Marketing and Business Development | — | — | Bartek release 2022; Food Ingredients First 2023 |
Dave Tapajna | Vice President of Sales | — | — | Bartek release 2019 |
John Burrows | Former President and CEO | Late 2018 to at least Jan 2023 | — | Bartek releases; Bakers Journal |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Country | Overlap with Bartek | Positioning |
|---|---|---|---|
Polynt Group | Italy | Maleic anhydride, malic and fumaric acid | Large integrated anhydrides and derivatives group; main Western rival |
Fuso Chemical | Japan | Malic acid | Long-established malic producer |
Thirumalai Chemicals | India | Maleic anhydride, malic and fumaric acid | Low-cost integrated Asian producer |
Changmao Biochemical Engineering | China | Malic and fumaric acid | Chinese organic acids producer |
Anhui Sealong Biotechnology | China | Malic acid | Chinese malic producer |
Yongsan Chemicals | South Korea | Malic and fumaric acid | Regional producer |
Isegen South Africa | South Africa | Malic and fumaric acid | Regional producer |
Jungbunzlauer | Switzerland | Citric and lactic acid (substitutes) | Fermentation-based acidulant leader |
Cargill | United States | Citric acid (substitute) | Scale agribusiness supplier |
Archer Daniels Midland | United States | Citric acid (substitute) | Scale agribusiness supplier |
Corbion | Netherlands | Lactic acid and preservation systems (substitutes) | Leader in lactic acid and bakery preservation |
Competitor Detail
| Metric | Bartek |
|---|---|
Revenue, latest (USD Mn) | 65 |
Recent Developments
Whether the new plant has started up as of October 2026 was not confirmed in public sources.
